This protocol allows CML and Ph+ ALL subjects who are resistant to or intolerant of imatinib mesylate, to potentially benefit from dasatinib. It is intended to provide patients with access to dasatinib while awaiting reimbursement decision in Korea and it will also provide additional data on the safety of dasatinib in Korean population
Drug: Dasatinib
tablet, Oral, 140mg/day, BID, until;
the time of reimbursement in Korea
the application for marketing authorization is withdrawn
the application for marketing authorization is denied
Other Name: Sprycel
Other Name: BMS-354825
Inclusion Criteria:
- Clinical diagnosis of CML or Ph+ ALL who have primary or acquired resistance to or intolerance of imatinib mesylate
- ECOG performance status score 0 - 2
- Adequate hepatic, renal function
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb, Korea